Company
Universal Ibogaine, Inc.
Headquarters: Vancouver, BC, Canada
CEO: Mr. Nicholas Peter Karos
Universal Ibogaine, Inc. Categories
Canada Healthcare BiotechnologyCanada Healthcare Canada Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Universal Ibogaine Inc. provides treatment for addiction patients in Canada. It provides ibogaine addiction treatment to patients suffering from opioid addiction; and operates clinics that offer non-medical detox, inpatient and outpatient treatment, and aftercare recovery programs, as well as addiction intervention services. The company was incorporated in 2018 and is based in Vancouver, Canada.
Stocks & Indices
Universal Ibogaine, Inc. has the following listings and related stock indices.
Stock: TSXV: IBO wb_incandescent